Live feed
·
INSIDERFilingvia Quantisnow
Sionna Therapeutics Inc. logo

Sionna Therapeutics (SION) director Orbimed Advisors sold 510,583 shares for $22.9M at an average $44.94 under a 10b5-1 plan

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Orbimed Advisors Llc (director at Sionna Therapeutics Inc., SION) reported that they sold 510,583 shares for $22.9M at an average $44.94 between Apr 14, 2026 and Apr 16, 2026. After these transactions the filing shows 3,020,119 shares held indirectly (See footnotes).

Reporting person
Orbimed Advisors Llc
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Apr 14, 2026Open-market sale (S)Common Stock1, 2, 3-47,814$44.51$2.13M3,482,888 indirect
Apr 15, 2026Open-market sale (S)Common Stock1, 2, 3-235,863$44.64$10.5M3,247,025 indirect
Apr 16, 2026Open-market sale (S)Common Stock1, 2, 3-226,906$45.34$10.3M3,020,119 indirect

Holdings before and after

  • Common Stock: 3,530,702 to 3,020,119 indirect, See footnotes

Footnotes from the filing

  1. 1. These securities were sold pursuant to a 10b5-1 plan.
  2. 2. These securities are held of record by OrbiMed Private Investments VIII, LP ( OPI VIII ). OrbiMed Capital GP VIII LLC ( GP VIII ) is the general partner of OPI VIII and OrbiMed Advisors LLC ( OrbiMed Advisors ) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  3. 3. This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act ), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Transaction codes in this filing

Open-market sale:
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

FAQ

What did Orbimed Advisors report in this SION Form 4?

Orbimed Advisors Llc (director at Sionna Therapeutics Inc., SION) reported that they sold 510,583 shares for $22.9M at an average $44.94 between Apr 14, 2026 and Apr 16, 2026. After these transactions the filing shows 3,020,119 shares held indirectly (See footnotes).

How many SION shares does Orbimed Advisors hold after this filing?

The filing shows 3,020,119 shares held indirectly (See footnotes) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

Was this SION insider sale made under a 10b5-1 plan?

The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.

What does transaction code S mean on an SEC Form 4?

Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

Historical context for SION

Across the 13 sessions after earlier SION headlines, the stock closed higher 5 times and lower 8 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

Earlier insider filings at SION

Quantisnow market dataNASDAQ
Sionna Therapeutics Inc. logo
SION
Sionna Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2025
Get push alerts for SION

Follow SION and get a push notification the moment its next story breaks.

Full SION profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SION (Sionna Therapeutics Inc.) and more on Quantisnow.